Department of Radiology, University of Washington Medical Center, Seattle, WA, USA.
AJR Am J Roentgenol. 2010 Sep;195(3):792-8. doi: 10.2214/AJR.09.4081.
The purpose of this article is to determine the frequency, outcomes, and imaging features of high-risk lesions initially detected by breast MRI, including atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, and radial scar.
A retrospective review of our MRI pathology database was performed to identify all lesions initially detected with MRI (January 2003 through May 2007) that underwent imaging-guided needle biopsy yielding high-risk histopathologic abnormalities. Patient age, clinical indication, MRI BI-RADS lesion features, biopsy method, and histopathologic diagnosis were recorded. The frequencies of high-risk findings at needle biopsy and rates of upgrade to malignancy at surgical excision were compared across lesion imaging features with Fisher's exact test.
Four hundred eighty-two MRI-detected suspicious lesions underwent needle biopsy. High-risk histopathologic abnormalities were present in 61 (12.7%) of 482 lesions: 51 (10.6%) atypical ductal hyperplasias, six (1.2%) atypical lobular hyperplasias, three (0.6%) lobular carcinomas in situ, and one (0.2%) radial scar. Correlation between the lesion site and pathology at surgical excision was confirmed for 39 of 61 lesions. Twelve (30.8%) of those 39 lesions were upgraded to malignancy (11 atypical ductal hyperplasias and one atypical lobular hyperplasia); five (41.7%) of the 12 malignancies were invasive cancer, and seven (58.3%) were ductal carcinomas in situ. No significant lesion features predictive of subsequent upgrade to malignancy were discovered.
There are no specific imaging features that predict upgrade for high-risk lesions when detected with MRI. Therefore, surgical excision is recommended because upgrade to invasive carcinoma or ductal carcinoma in situ can occur in up to 31% of cases, regardless of biopsy technique.
本文旨在确定通过乳腺 MRI 最初检测到的高危病变的频率、结果和影像学特征,包括非典型导管增生、非典型小叶增生、小叶原位癌和放射状瘢痕。
对我们的 MRI 病理数据库进行回顾性研究,以确定所有通过 MRI(2003 年 1 月至 2007 年 5 月)最初检测到的病变,这些病变通过影像学引导的针吸活检显示出高危的组织病理学异常。记录患者年龄、临床指征、MRI BI-RADS 病变特征、活检方法和组织病理学诊断。采用 Fisher 确切检验比较病变影像学特征与针吸活检高危发现的频率和手术切除恶性肿瘤升级率。
482 个 MRI 检测到的可疑病变接受了针吸活检。61 个(12.7%)病变存在高危组织病理学异常:51 个(10.6%)非典型导管增生、6 个(1.2%)非典型小叶增生、3 个(0.6%)小叶原位癌和 1 个(0.2%)放射状瘢痕。在 39 个接受手术切除的病变中,确认了病变部位与病理的相关性。其中 12 个(30.8%)病变升级为恶性肿瘤(11 个非典型导管增生和 1 个非典型小叶增生);12 个恶性肿瘤中 5 个(41.7%)为浸润性癌,7 个(58.3%)为导管原位癌。未发现具有预测高危病变恶性肿瘤升级的特定影像学特征。
当通过 MRI 检测到高危病变时,没有特定的影像学特征可以预测其升级。因此,推荐进行手术切除,因为无论活检技术如何,高危病变中有 31%可能升级为浸润性癌或导管原位癌。